Terms and conditions: semantic complexity and aspirin resistance
about
sameAs
Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating AspirinAspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysisAspirin resistanceMedications for the treatment of acute coronary syndromesEnhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trialAspirin resistance and its implications in clinical practiceDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsCritical Overview on the Benefits and Harms of Aspirin.Platelets: still a therapeutical target for haemostatic disorders.Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort studyResistance to aspirin and clopidogrel therapy.Emerging therapies for acute coronary syndromesLatest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Clinical consequences of aspirin and clopidogrel resistance: an overview.Identifying determinants of variability to tailor aspirin therapy.Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5-y prospective cohort study.Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.Aspirin resistance.Antiplatelet resistance in outpatients with monitored adherence.Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.Obesity: is it a major risk for developing aspirin resistance in older adults?
P2860
Q22306342-A683CF20-9975-43FB-BB92-C67ACE7B9CF9Q24645413-75AE5FD3-2AF6-4120-91F4-C6F3D0A0DF2FQ28187611-F1C5D4CA-95DA-47B8-9F8F-21BE3C2233ABQ28193674-D2162EC6-E827-45DC-9DEB-3522D5F74623Q28193982-EE1754EE-8797-4949-A2C8-BD1359EDC993Q28194069-28E0F440-B6A9-4B09-AD46-EC28A642FD00Q28200895-E39C73F9-7264-42CF-A52F-9576B2B24CB2Q33664298-064365C4-9BCD-4034-B057-FD5FD8FFC20DQ34486685-3855B0DF-5A50-4939-B617-B4D90D295057Q34536091-D9C615E2-7B6D-400C-AD0C-B19427DC3AE4Q34635205-A9807671-6D0C-449D-A104-E400A043EC67Q37807524-519390DF-0C21-4402-93AB-BDB4B047B963Q37949587-3D84C22F-3587-4D9F-8380-A3186A6C5976Q38012079-A3D3E169-6849-44E8-B072-34DFA874D7C0Q38083817-C7F4B4B6-4652-42AA-977C-F171E5A47517Q38087384-D5930FEC-7EE5-4701-918B-3712CB9016B0Q40877690-93A1230E-0F57-4F81-A6D8-47559DBC22ACQ42167236-03BA38BD-A7ED-42A2-9FC2-9EAFF343DA11Q42641720-F5ED1131-579C-4370-82D0-E5D693B64772Q43888035-BF3662C5-CCE6-4F0A-BF76-263C383011B6Q45337198-03A90AA2-EF21-4CC8-9883-DFB8EE3AD30BQ46373377-3F328A79-D1D9-47B4-B4E3-9BD987E925AB
P2860
Terms and conditions: semantic complexity and aspirin resistance
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Terms and conditions: semantic complexity and aspirin resistance
@ast
Terms and conditions: semantic complexity and aspirin resistance
@en
Terms and conditions: semantic complexity and aspirin resistance
@nl
type
label
Terms and conditions: semantic complexity and aspirin resistance
@ast
Terms and conditions: semantic complexity and aspirin resistance
@en
Terms and conditions: semantic complexity and aspirin resistance
@nl
prefLabel
Terms and conditions: semantic complexity and aspirin resistance
@ast
Terms and conditions: semantic complexity and aspirin resistance
@en
Terms and conditions: semantic complexity and aspirin resistance
@nl
P2093
P1433
P1476
Terms and conditions: semantic complexity and aspirin resistance
@en
P2093
Charles H Hennekens
Garret A FitzGerald
Karsten Schror
Steven Weisman
P304
P356
10.1161/01.CIR.0000142056.69970.DB
P407
P577
2004-09-21T00:00:00Z